BIOLASE (NASDAQ:BIOL) Coverage Initiated by Analysts at StockNews.com

Analysts at StockNews.com started coverage on shares of BIOLASE (NASDAQ:BIOLGet Free Report) in a research note issued to investors on Tuesday. The firm set a “sell” rating on the medical technology company’s stock.

Separately, Benchmark reiterated a “speculative buy” rating and issued a $0.40 price target on shares of BIOLASE in a research note on Wednesday, October 2nd.

Read Our Latest Stock Analysis on BIOL

BIOLASE Price Performance

Shares of BIOL opened at $0.01 on Tuesday. BIOLASE has a 1 year low of $0.02 and a 1 year high of $1.94. The company has a 50 day simple moving average of $0.01 and a two-hundred day simple moving average of $0.04. The firm has a market cap of $302,333.35, a P/E ratio of 0.00 and a beta of 0.67.

BIOLASE Company Profile

(Get Free Report)

BIOLASE, Inc, together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications.

Featured Articles

Receive News & Ratings for BIOLASE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOLASE and related companies with MarketBeat.com's FREE daily email newsletter.